TmPSMA-02
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
September 24, 2025
TmPSMA-02 in mCRPC
(clinicaltrials.gov)
- P1 | N=8 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting | N=18 ➔ 8
Enrollment change • Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
February 06, 2024
TmPSMA-02 in mCRPC
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: University of Pennsylvania | Not yet recruiting ➔ Recruiting
Enrollment open • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
September 21, 2023
TmPSMA-02 in mCRPC
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: University of Pennsylvania
Metastases • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
August 18, 2023
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
(clinicaltrials.gov)
- P1/2 | N=1 | Terminated | Sponsor: Tceleron Therapeutics, Inc. | N=114 ➔ 1 | Trial completion date: Jan 2032 ➔ May 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2028 ➔ May 2023; Study was stopped Sponsor discretion. No patients were dosed.
Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
October 06, 2022
Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells
(SITC 2022)
- P1 | "Background We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275 ) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)...Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC...The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study."
CAR T-Cell Therapy • Clinical • Oncology • Prostate Cancer • CD2 • CSF2 • IL18 • IL2 • IL6 • TGFB1
December 21, 2022
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
(clinicaltrials.gov)
- P1/2 | N=114 | Active, not recruiting | Sponsor: Tmunity Therapeutics | Recruiting ➔ Active, not recruiting
Enrollment closed • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CAST
October 19, 2022
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
(clinicaltrials.gov)
- P1/2 | N=114 | Recruiting | Sponsor: Tmunity Therapeutics | Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CAST
1 to 7
Of
7
Go to page
1